

Global Health (Medanta)

Ramp up of new units to drive earnings, maintain BUY

Global Health' revenue (up 19% y/y) beat ARe/Ce by 6/3% in Q3FY26, while EBITDA (down 10% y/y) missed ARe/Ce by 4/8%. While PAT fell 8% y/y, APAT plunged 33.5%, owing to adjustment for labour code in the exceptional items. Notably, ARPOB rose 10% y/y to Rs67,361. While overall occupancy stood at 59% vs. 64% in both Q3FY25 and Q2FY26, occupancy at new Lucknow and Patna units fell to 62% vs. 70% in Q2FY26. Notably, the margin of new units declined 213bps y/y to 31.7%. It announced a 400-bed hospital in South Delhi in partnership with DLF, for which construction is underway at site 1. Medanta added 144 beds in Q3 (42/102 in Patna/Noida) taking the total bed count to 3,579.

Loss at Noida Unit, Seasonality and Higher Overheads Drag EBITDA: Consolidated revenue grew 19% y/y to Rs11.2bn (vs. ARe of Rs10.5bn), aided by better performances in Lucknow and Patna. Medanta added 102 beds in Noida in Q3, taking its total bed count to 328 as of Dec-25. The unit generated of Rs343m revenue in Q3 and reported Rs320m EBITDA loss in Q3FY26, dragging the overall EBITDA. Thus, loss at Noida unit (Rs320m) in Q3FY26 along with seasonality and higher overheads led to 10% y/y decline in EBITDA to Rs2.1bn.

Higher ALOS, Better Speciality-mix Drive ARPOB: Aided by higher ALOS and better speciality-mix, ARPOB increased to Rs67,361/day in Q3FY26. The management projects 5-7% ARPOB run rate for next 3 years. Noida ARPOB remained similar to that of Delhi.

Capacity Expansion on Track: Medanta announced 400 beds in partnership with DLF. Notably, land possession is completed for Guwahati unit, while other approvals are awaited. It is on the track to achieve bed count of >6,000 beyond FY27e with Rs390bn capex over the next 5 years. Maintenance capex is pegged at Rs4.5bn over the next 3 years, while project capex is estimated at Rs34.5bn to be funded through debt and internal accruals.

Outlook and Valuation: We expect steady momentum to continue led by: (a) greater capacity utilisation at new hospitals; (b) rising share of international patients in overall revenue; and (c) better ARPOB on superior payor-mix. Expecting its revenue/EBITDA/PAT to clock 16/16/18% CAGR over FY25-28e, we trim our FY26/27/28e EBITDA estimate by 9/3/7%. We maintain BUY rating on the stock with a revised TP of Rs1,450 (from Rs1,541 earlier), valuing it at 26x FY28e EV/EBITDA. **Key Risks:** (a) Delay in project execution; (b) price control; (c) decline in international business.

Key Financials (Y/E Mar)	FY24	FY25	FY26e	FY27e	FY28e
Sales (Rs m)	32,751	36,923	43,169	50,188	58,008
Net profit (Rs m)	4,782	4,814	5,211	7,104	8,633
EPS (Rs)	17.8	19.8	19.4	26.4	32.1
P/E (x)	64.2	57.8	58.9	43.2	35.6
EV / EBITDA (x)	37.5	34.1	33.0	24.9	20.1
P/BV (x)	7.6	6.5	5.7	4.8	4.0
RoE (%)	17.9	16.9	14.3	16.7	17.1
RoCE (%)	15.3	14.9	13.0	14.8	15.3
Dividend yield (%)	-	-	-	-	-
Net debt / equity (x)	-0.3	-0.2	-0.3	-0.4	-0.5

Source: Company, Anand Rathi Research

Rating: **BUY**

Target Price (12-mth): Rs.1,450


Share Price: Rs 1,143

Key Data	MEDANTA IN / GLOH.BO
52-week high / low	Rs1457 / 1010
Sensex / Nifty	84274 / 25935
Market cap	Rs314bn
Shares outstanding	269m

Shareholding Pattern (%)	Dec'25	Sep'25	Jun'25
Promoters	33.0	33.0	33.0
- of which, Pledged	0.0	0.0	0.0
Free float	67.0	67.0	67.0
- Foreign institutions	10.5	11.4	11.5
- Domestic institutions	14.0	13.0	12.2
- Public	42.4	42.6	43.2

Estimates Revision (%)	FY26e	FY27e	FY28e
Sales	6.3	3.8	(0.6)
EBITDA	(9.0)	(3.2)	(7.0)
PAT	(11.2)	(3.7)	(8.3)

Relative Price Performance



Source: Bloomberg

Himanshu Binani
Research Analyst

Anubhav Sangal
Research Associate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Quick Glance – Financial and Valuations (consolidated)

Fig 1 – Income Statement (Rs m)

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
Revenues	32,751	36,923	43,169	50,188	58,008
Growth (%)	20.9	12.7	16.9	16.3	15.6
Raw material	7,594	8,797	9,497	11,041	12,762
Employee & other expens.	17,167	19,356	22,340	25,566	29,236
EBITDA	7,991	8,771	8,925	11,520	13,799
EBITDA margins (%)	24.4	23.8	20.7	23.0	23.8
- Depreciation	1,727	1,937	2,179	2,341	2,503
Other income	747	791	870	914	959
Interest expense	739	653	761	747	897
PBT	6,271	6,473	6,854	9,346	11,358
Effective tax rates (%)	24	24	24	24	24
+ Associates / (Minorities)	-1	-1	-1	-1	-1
Adj. income	4,782	5,313	5,211	7,104	8,633
Extraord. items (loss)/profit	-	-499	-	-	-
Reported PAT	4,782	4,814	5,211	7,104	8,633
WANS	269	269	269	269	269
FDEPS (Rs)	17.8	19.8	19.4	26.4	32.1

Fig 2 – Balance Sheet (Rs m)

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
Share capital	537	537	537	537	537
Net worth	29,056	33,864	39,075	46,179	54,812
Debt	4,193	3,279	4,479	4,979	5,979
Minority interest	-0	11	10	8	7
Deferred tax liability / (asset)	-372	-330	-330	-330	-330
Capital employed	32,878	36,824	43,233	50,836	60,468
Net tangible assets	22,316	25,075	27,675	28,334	28,831
CWIP (tang. and intang.)	3,918	5,398	5,398	5,398	5,398
Investments (strategic)	1	27	30	33	36
Investments (financial)	-	-	-	-	-
Current assets (excl. C&CE)	4,440	5,608	6,146	6,817	7,565
Cash	11,753	11,223	17,043	24,847	34,927
Current liabilities	9,550	10,508	13,059	14,593	16,289
Working capital	-5,110	-4,900	-6,913	-7,776	-8,724
Capital deployed	32,878	36,824	43,233	50,836	60,468

Fig 3 – Cashflow Statement (Rs m)

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
PBT	6,271	6,473	6,854	9,346	11,358
+ Non-cash items	2,466	2,590	2,941	3,088	3,400
Oper. profit before WC changes	8,737	9,063	9,795	12,434	14,758
- Incr./ (decr.) in WC	459	997	-2,013	-863	-948
Others incl. taxes	1,412	1,143	1,645	2,243	2,726
Operating cash-flow	6,866	6,922	10,163	11,053	12,980
- Capex (tangible + intangible)	2,786	5,165	4,779	3,000	3,000
Free cash-flow	4,080	1,757	5,384	8,053	9,980
Acquisitions	-	-	-	-	-
- Div. (incl. buyback & taxes)	680	642	761	747	897
+ Equity raised	0	0	-	-	-
+ Debt raised	-4,459	-330	1,200	500	1,000
- Fin. investments	1,622	2,044	-	-	-
- Misc. items (CFI and CFF)	-	-	-	-	-
Net cash-flow	-2,681	-1,259	5,823	7,807	10,083

Source: Company, Anand Rathi Research

Fig 5 – Price Movement




Source: Bloomberg

Fig 4 – Ratio Analysis


Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
P/E (x)	64.2	57.8	58.9	43.2	35.6
EV / EBITDA (x)	37.5	34.1	33.0	24.9	20.1
EV / Sales (x)	6.5	5.8	4.8	4.0	3.3
P/B (x)	7.6	6.5	5.7	4.8	4.0
RoE (%)	17.9	16.9	14.3	16.7	17.1
RoCE (%) - after tax	15.3	14.9	13.0	14.8	15.3
RoIC (%) - after tax	17.9	16.9	14.3	16.7	17.1
DPS (Rs)	-	-	-	-	-
Dividend yield (%)	-	-	-	-	-
Dividend payout (%)	-	-	-	-	-
Net debt / equity (x)	-0.3	-0.2	-0.3	-0.4	-0.5
Receivables (days)	23	25	25	23	23
Inventory (days)	31	28	35	42	42
Payables (days)	92	79	107	130	131
CFO : PAT (%)	144	130	195	156	150

Source: Company, Anand Rathi Research


Fig 6 – Steady EBITDA growth at New Hospitals, led by Patient Volume



Source: Company

Fig 7 – Occupancy dip due to newer bed additions

Source: Company, Anand Rathi Research

Fig 8 – ARPOB Growth was led by a Better Payor-mix


Source: Company, Anand Rathi Research

Fig 9 – Quarterly Trend

(Rs m)	Q3FY26	Q3FY25	Y/Y(%)	Q2 FY26	Q/Q(%)	9MFY26	9MFY25	YoY (%)	FY26E	FY25	y/y (%)
Revenue	11,210	9,434	18.8	10,992	2.0	32,511	27,611	17.7	43,169	36,923	16.9
Raw material	2,557	2,292	11.5	2,556	0.0	7,503	6,661	12.6	9,497	8,797	8.0
Staff costs	2,807	2,050	36.9	2,743	2.3	8,114	6,205	30.8	9,497	8,245	15.2
Others	3,674	2,680	37.1	3,384	8.6	10,142	8,138	24.6	12,843	11,110	15.6
Total expenditure	9,038	7,023	28.7	8,683	4.1	25,759	21,004	22.6	31,837	28,153	13.1
EBITDA	2,173	2,412	(9.9)	2,309	(5.9)	6,752	6,607	2.2	8,925	8,771	1.8
Depreciation	612	519	18.0	497	23.1	1,560	1,445	8.0	2,179	1,937	12.5
EBIT	1,561	1,893	(17.5)	1,812	(13.9)	5,192	5,162	0.6	6,746	6,833	(1.3)
Less: Interest expense	215	163	32.2	171	25.7	524	646	(18.9)	761	653	16.7
Add: Other income	218	160	35.9	197	10.4	620	562	10.3	870	791	10.0
Profit before tax	1,564	1,891	(17.3)	1,838	(14.9)	5,288	5,077	4.1	6,854	6,972	(1.7)
Less: Provision for tax	248	462	(46.4)	414	(40.2)	1,153	1,339	(13.9)	1,645	1,659	(0.9)
Adj. profit	1,316	1,429	(7.9)	1,424	(7.6)	4,134	3,738	10.6	5,209	5,312	(1.9)
Add: Exceptional items	-366	0	NA	160	NA	-10	0	NA	-	-499	NA
Reported profit	950	1,429	(33.5)	1,584	(40.0)	4,134	3,738	10.6	5209	4813	8.2
No. of diluted shares outstanding (m)	268	268		268		268	268		269	269	0
Adj. diluted EPS (Rs)	4.9	5.3	(7.9)	5.3	(7.6)	15.4	13.9	10.6	19.4	19.8	(1.9)
As % of net revenue											
Raw material	22.8	24.3		23.2		23.1	24.1		22.0	23.8	
Staff expenses	25.0	21.7		25.0		25.0	22.5		22.0	22.3	
Other expenses	32.8	28.4		30.8		31.2	29.5		29.8	30.1	
EBITDA	19.4	25.6		21.0		20.8	23.9		20.7	23.8	
Net profit	11.7	15.1		13.0		12.7	13.5		12.1	14.4	


Source: Company

Fig 10 – Specialty-mix (Q3FY26)



Source: Company, Anand Rathi Research

Fig 11 – Payor-mix (Q3FY26)



Source: Company, Anand Rathi Research

Outlook and Valuation

Looking ahead, we expect steady momentum to continue led by: (a) greater capacity utilisation at new hospitals; (b) rising share of international patients; and (c) better ARPOB aided by a superior payor-mix. Medanta is on track to scale up its Lucknow and Patna capacity to be partially mitigated by drag from upcoming Noida and Ranchi units in Q3. Considering strong business prospects, we expect its revenue/EBITDA/earnings to clock 16/16/18% CAGR over FY25-28e, and accordingly we trim our EBITDA estimate by 9/3/7% for FY26/27/28e. At CMP, the stock trades at 25/20x FY27/28e EV/EBITDA and 43/36x P/E. We maintain BUY rating on the stock with a revised TP of Rs1,450 (from Rs1,541 earlier), valuing it at 26x FY28e EV/EBITDA.

Fig 12 – Change in Estimates

(Rs m)	FY26e		FY27e		FY28e	
	Old	New Change (%)	Old	New Change (%)	Old	New Change (%)
Revenue	40,623	43,169	6.3	48,351	50,188	3.8
EBITDA	9,807	8,925	(9.0)	11,898	11,520	(3.2)
EBITDA Margin (%)	24.1	20.7	-346.7	24.6	23.0	-165.3
PAT	5,869	5,211	(11.2)	7,379	7,104	(3.7)
EPS	21.9	19.4	(11.4)	27.5	26.4	(3.8)


Source: Anand Rathi Research

Fig 13 – Valuation

(Rs m)	FY28e
EBITDA	13,799
stake- 100%	13,799
Target multiple (x)	26
EV	3,60,146
Less net debt	-28,948
Derived market cap	3,89,094
No. of shares (m)	269
Target price (Rs)	1,450
CMP (Rs)	1,143
Upside (%)	27%


Source: Bloomberg, Anand Rathi Research

Fig 14 – P/E Chart



Source: Bloomberg, Anand Rathi Research

Fig 15 – EV/EBITDA Chart



Source: Bloomberg, Anand Rathi Research

Risks

- Delay in project execution.
- Regulatory risks i.e., price control, margin cap, mandatory bed allocation.
- Decline in international business.


Appendix

Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies

Rating and Target Price History (as of 5 February 2026)



Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps, Mid Caps & Small Caps as described in the Ratings Table below:

Ratings Guide (12 months)

	Buy	Hold	Sell
Large Caps (Top 100 companies)	>15%	0-15%	<0%
Mid Caps (101st-250th company)	>20%	0-20%	<0%
Small Caps (251st company onwards)	>25%	0-25%	<0%

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015, BSE Enlistment Number – 5048 date of Regn 25 July 2024) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd (BSE), National Stock Exchange of India Ltd. (NSEIL),Multi Commodity Exchange of India Limited (MCX),National Commodity & Derivatives Exchange Limited (NCDEX), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. (CDSL), ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. ARSSBL does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding taxation aspects of any potential investment.

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No
ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	No

NOTICE TO US INVESTORS:

This research report is the product of Anand Rathi Share and Stock Brokers Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated person(s) of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances, and trading securities held by a research analyst account.

Research reports are intended for distribution only to Major U.S. Institutional Investors as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act of 1934 (the Exchange Act) and interpretations thereof by the U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this research report is not a Major U.S. Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated, and/or transmitted onward to any U.S. person which is not a Major U.S. Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major U.S. Institutional Investors, Anand Rathi Share and Stock Brokers Limited has entered into a Strategic Partnership and chaperoning agreement with a U.S. registered broker-dealer: Banc Trust Securities USA. Transactions in securities discussed in this research report should be affected through Banc Trust Securities USA.

1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

© 2026. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

As of the publication of this report, ARSSBL does not make a market in the subject securities.

Registration granted by SEBI, Enlistment as RA and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Additional information on recommended securities/instruments is available on request.

Compliance officer: Deepak Kedia, email id: deepakkedia@rathi.com, Contact no. +91 22 6281 7000
Grievance officer: Madhu Jain, email id: grievance@rathi.com, Contact no. +91 22 6281 7191

ARSSBL registered address: Express Zone, A Wing, 10th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.
Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.